| Literature DB >> 32021067 |
Michele De Maria1,2, Danilo Iannetta1, Luca Cimino3, Marco Coassin4, Luigi Fontana1.
Abstract
Cystoid macular edema (CME) is an infrequent, though potentially visually impairing, complication after uneventful cataract surgery. Rupture of the blood-aqueous barrier, with leakage of serum proteins into the aqueous humour, is the main pathogenic factor. However, only a few studies investigated the potential correlation between anterior chamber (AC) inflammation and the risk of cystoid macular changes occurring after surgery. This review aims to identify evidence of a correlation between AC inflammation and the risk of pseudophakic CME. One hundred eighty-seven prospective trials investigating AC inflammation after uncomplicated cataract surgery were identified. Methods of analysis of AC inflammation and the frequency of macular changes were recorded. In the majority (51%) of the studies, inflammation was assessed by clinical grading, followed by laser flare and cell photometry (LFCP) (42%) and aqueous humour sample (4%). Few studies (4%) adopted a combined LFCP and aqueous sample or clinical grading analysis. Sixteen (9%) studies investigated AC inflammation and macular changes by OCT (7%) or fluorescein angiography (2%). Correlation between the amount of postoperative AC inflammation and frequency of CME was documented in 7 studies, not confirmed in 2 studies, and not examined in the other 7. LFCP, more than the other methods of analysis, correlated with the frequency of CME postoperatively. Investigation of the relationship between AC inflammation and the risk of CME changes requires the adoption of quantitative methods of analysis of the inflammatory response after surgery. For this purpose, due to the low level of inflammation in the AC after uncomplicated cataract surgery, LFCP, more than subjective clinical grading, seems a more sensitive and reproducible method of measurement. Inflammation assessment after cataract surgery has a potential role in predicting the risk of CME development and may help to titrate the duration and intensity of treatment in relation to the surgical inflammatory response.Entities:
Keywords: anterior chamber inflammation; anterior segment optical coherence tomography; aqueous humour sample; cataract surgery; clinical grading; cystoid macular edema; laser flare photometry
Year: 2020 PMID: 32021067 PMCID: PMC6957928 DOI: 10.2147/OPTH.S237405
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Figure 1Literature review process.
Abbreviations: LFCP, Laser Cell and Flare Photometry; AS-OCT, Anterior Segment Optical Coherence Tomography; FA, Fluorescein Angiography; OCT, Optical Coherence Tomography.
Literature Review on Clinical Trials and Correlation with the Risk of CME
| Author | Year of Publication | Title | Research Field | Study Type | Surgical Technique | Sample Size | Follow-up | Index Test to Asses Inflammation | Macula Assessment | Incidence of CME [Clinical Significant CME] | Correlation Flare - CME |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rossetti | 1996 | Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. | Drug efficacy | Prospective | ECCE, phacoemulsification | 88 | 6 months | Clinical grading | Fluorescein angiography | 9% [1%] | Not investigated |
| Gallenga | 1997 | Efficacy of diclofenac eye drops in preventing postoperative inflammation and long-term cystoid macular edema. Italian Diclofenac Study Group. | Drug efficacy | Prospective | ECCE | 281 | 5 months | Clinical grading | Fluorescein angiography | 5% | Not investigated |
| Ursell | 1999 | Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. | Surgical | Prospective | Phacoemulsification | 34 | 2 months | Laser Flare Cells Meter | Fluorescein angiography | 56% | Flare and cells were higher in CME patients at day 60, but the difference was not statistically significant. |
| Donnenfel | 2006 | Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. | Drug efficacy | Prospective | Phacoemulsification | 100 | 3 months | SUN grading | OCT | [4%] | Not investigated |
| Miyanaga | 2009 | Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery | Drug efficacy | Prospective | Phacoemulsification | 72 | 2 months | Laser Flare Cells Meter | OCT | 1 case | Aqueous flare values in the subject with CME were higher than those for all other cases |
| Maca | 2010 | Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eye drops after cataract surgery. | Drug | Prospective | Phacoemulsification | 102 | 1 month | Laser Flare Cells Meter | OCT | 0% | No correlation was found |
| Dieleman | 2011 | Single perioperative subconjunctival steroid depot versus postoperative steroid eye drops to prevent intraocular inflammation and macular edema after cataract surgery. | Drug efficacy | Prospective | Phacoemulsification | 400 | 1 month | Laser Flare and Cell Meter | OCT | 6.5% [2.8%] | Not investigated |
| Chu | 2013 | Aqueous cytokines as predictors of macular edema in non-diabetic patients following uncomplicated phacoemulsification cataract surgery | Surgical technique | Prospective | Phacoemulsification | 288 | 4 weeks | Aqueous Humor Sample | OCT | 8.13% | Preoperative levels of IL-1β, IL-6, MCP-1, VEGF, and IL-10 may predispose to CME development. |
| Wang | 2013 | Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. | Drug efficacy | Prospective | Phacoemulsification | 167 | 2 months | Laser Flare and Cell Meter | OCT | 4% | Not investigated |
| Ersoy | 2013 | Aqueous flare is increased in patient with clinical significant cystoid macular edema after cataract surgery | Surgical technique | Prospective | Phacoemulsification | 121 | - | Laser Flare Meter | OCT | - | Patients with CME had significantly higher flare values compared with pseudophakic patients |
| Conrad-Hengerer | 2014 | Femtosecond laser-induced macular changes and anterior segment inflammation in cataract surgery. | Surgical | Prospective | Femtosecond assisted cataract surgery Vs Phacoemulsification | 208 | 6 months | Laser Flare Meter | OCT | 0% | Laser flare values correlate with the postoperative macular thickness. |
| Zaczek | 2014 | Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. | Drug | Prospective | Phacoemulsification | 152 | 1.5 month | Laser Flare Meter | OCT | 1.3% [0.6%] | No correlation was found |
| Coassin | 2016 | Bromfenac ophthalmic solution 0.09% as an adjunctive therapy to topical steroids after cataract surgery in pseudoexfoliation syndrome. | Drug | Prospective | Phacoemulsification | 62 | 1 month | Laser Flare Meter | OCT | 13.8% | Patients treated with a steroids single therapy presented a higher flare higher incidence of CME at 1 month after surgery |
| Giannaccare | 2018 | The Comparative Efficacy and Tolerability of Diclofenac 0.1% and Bromfenac 0.09% Ophthalmic Solutions after Cataract Surgery. | Drug efficacy | Prospective | Phacoemulsification | 130 | 1 month | Laser Flare Meter | OCT | 2% | Not investigated |
| Wielders | 2018 | European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. | Drug efficacy | Prospective | Phacoemulsification | 914 | 3 months | SUN grading | OCT | 5% [3.4%] | Not investigated |
| Coassin | 2019 | Anterior Chamber Inflammation After Cataract Surgery: A Randomized Clinical Trial Comparing Bromfenac 0.09% to Dexamethasone 0.1%. | Drug | Prospective | Phacoemulsification | 76 | 1 month | Laser Flare Meter | OCT | 2.7% | Bromfenac single therapy or dexamethasone are equally effective in reducing AC inflammation, but patients treated with steroids showed a higher incidence of CME. |
Abbreviations: CME, Cystoid Macular Edema; OCT, Optical Coherence Tomography; SUN, Standardize Uveitis Nomenclature.